Viking Therapeutics announced it will present two posters at the 33rd European Congress on Obesity highlighting data from its Phase 2 trial of VK2735, an oral and subcutaneous dual GLP-1/GIP receptor agonist for obesity treatment. The Phase 2 VENTURE-Oral trial showed significant weight loss and good tolerability over 13 weeks. Additionally, Viking shared enrollment details of the ongoing Phase 3 VANQUISH-1 trial targeting adults with obesity or overweight with related health issues. These presentations mark important steps in VK2735's clinical development, with further data expected from the Phase 3 study.
Jefferies increased its price target for Ryman Hospitality Properties to $145, indicating a potential 16.94% upside from its current price of $123.99. The positive outlook is supported by the company's record Revenue Per Available Room (RevPAR) and 2...
Pfizer is moving its business focus away from COVID-19 products to its broader non-COVID portfolio, which grew 5% in Q2 2026. The company beat earnings estimates by 12% and raised its revenue guidance by $500 million, signaling strong financial healt...
Coherent Corp reported strong Q4 earnings with revenue of $2.05 billion, surpassing analyst expectations of $1.98 billion and marking a 34% increase from last year. The company's non-GAAP EPS rose to $1.74, beating estimates and reflecting growing de...
The tech sector saw strong gains led by Dell Technologies, whose AI server business grew by 757%, driving its stock up nearly 10% to $484.49. Other companies like Nokia, Hewlett Packard Enterprise, Resideo Technologies, and Oracle also posted signifi...
Several stocks experienced declines despite varying news. Pinterest shares fell due to legal investigations over alleged misleading of investors about advertising revenue and tariffs. Tapestry's stock dropped ahead of its fourth-quarter earnings repo...
